Analysts Set Vor Biopharma Inc. (NYSE:VOR) Target Price at $5.63

Vor Biopharma Inc. (NYSE:VOR - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the ten ratings firms that are currently covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $5.63.

Several brokerages have commented on VOR. Oppenheimer reaffirmed an "outperform" rating and issued a $8.00 price objective on shares of Vor Biopharma in a research report on Friday, March 21st. HC Wainwright raised shares of Vor Biopharma from a "neutral" rating to a "buy" rating and set a $3.00 price objective on the stock in a research report on Monday, June 30th. Jones Trading lowered shares of Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 8th. Baird R W lowered shares of Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 8th. Finally, JMP Securities reaffirmed a "market perform" rating and issued a $6.00 price objective on shares of Vor Biopharma in a research report on Friday, May 9th.

Vor Biopharma Trading Up 30.0%

Shares of VOR traded up $0.44 during trading hours on Friday, reaching $1.89. 24,491,873 shares of the stock traded hands, compared to its average volume of 4,248,899. The stock has a fifty day simple moving average of $0.45 and a 200 day simple moving average of $0.85. Vor Biopharma has a 52 week low of $0.13 and a 52 week high of $2.04. The company has a market cap of $235.55 million, a price-to-earnings ratio of -1.14 and a beta of 2.04.

Institutional Trading of Vor Biopharma

Hedge funds and other institutional investors have recently modified their holdings of the business. GABELLI & Co INVESTMENT ADVISERS INC. bought a new stake in shares of Vor Biopharma in the fourth quarter valued at approximately $33,000. Money Concepts Capital Corp raised its position in shares of Vor Biopharma by 106.1% in the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock valued at $37,000 after purchasing an additional 26,535 shares during the period. Virtu Financial LLC bought a new stake in shares of Vor Biopharma in the fourth quarter valued at approximately $60,000. XTX Topco Ltd bought a new stake in shares of Vor Biopharma in the fourth quarter valued at approximately $80,000. Finally, Goldman Sachs Group Inc. grew its stake in Vor Biopharma by 218.2% during the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock valued at $61,000 after acquiring an additional 58,247 shares in the last quarter. Institutional investors own 97.29% of the company's stock.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.